Compare Nvidia Corp (NVDA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Novo Nordisk A/S — how do they compare? Nvidia Corp trades at $234 (market cap $5.57T), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Nvidia Corp is far larger — about 33.7× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and Novo Nordisk A/S for 116 Days on average.
| NVDA | NVO | |
|---|---|---|
Market Cap | $5.57T | $165.31B |
Volume | 117,720,595 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $239.27 | $63.98 |
52-Week Low | $165.17 | $35.29 |
Typical Hold Time | 115 Days | 116 Days |
Enterprise Value | $5.54T | $179.56B |
Dividend Yield | 0.43% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid a broader tech sector rotation. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 55.84% net income margin and consistent earnings beats. Revenue growth accelerated to $130.50 billion in 2025, with analyst consensus remaining overwhelmingly positive.
The outlook for NVDA is favorable, driven by sustained AI chip demand and a $339.17 average price target implying significant upside. Key risks include heightened competition, market volatility from geopolitical tensions, and the stock's premium valuation. Long-term growth prospects remain robust, though near-term volatility may persist.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
